Biotechnology companies secured $1.3 billion in venture capital investments during the second quarter of 2013, a 41% increase compared with the previous quarter, according to a new MoneyTree Report. The number of biotech-related deals grew 4%, to 103. "Life sciences investment is poised for a slow and steady recovery, provided we can continue to see progress on the regulatory front," National Venture Capital Association President Mark Heesen said.

Related Summaries